This is an auto-generated stub page built from atlas entry frontmatter. A richer
hand-crafted page is planned. See the
atlas source
for the full entry including detailed body sections.
sstr2
SSTR2
SSTR2 (somatostatin receptor type 2) is the Gi-coupled GPCR mediating antiproliferative and antisecretory somatostatin signaling; SSTR2 is overexpressed in most well-differentiated NETs → octreotide/lanreotide SSA therapy and lutetium-177 DOTATATE PRRT (NETTER-1 trial).
Entry Metadata
| Field | Value |
|---|---|
| ID | sstr2 |
| Name | SSTR2 |
| Status | draft |
| Last reviewed | 2026-06-06 |
| Atlas | 01-human |
| Scale | 03-molecular |
Cross-Atlas Connections
Sources
- Rinke A, Müller HH, Schade-Brittinger C, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol. 2009;27(28):4656-4663. · PubMed 19704057
- Strosberg J, El-Haddad G, Wolin E, et al. Phase 3 trial of 177Lu-DOTATATE for midgut neuroendocrine tumors. N Engl J Med. 2017;376(2):125-135. · PubMed 28076709